The phase 3 COMPOSE trial is the second trial to look at 177Lu-edotreotide in somatostatin receptor-positive disease.
The phase 3 COMPOSE study will evaluate the efficacy of lutetium 177Lu-edotreotide (177Lu-edotreotide) versus best standard of care in well-differentiated aggressive grade 2 and grade 3 somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (NETs), according to a press release by ITM Isotope Technologies. 1
177Lu-edotreotide is composed of the medical radioisotope no-carrier-added n.c.a. lutetium-177 and edotreotide, a synthetic form of the peptide hormone somatostatin which targets neuroendocrine tumor-specific receptors. Edotreotide binds to these receptors and delivers lutetium-177 directly onto the disease neuroendocrine cells. This causes it to accumulate in the tumor site.
The COMPOSE trial (NCT04919226) has a target enrollment of 202 participants and an estimated completion date of September 2026. The primary end point of the trial is progression-free survival. The secondary end point is overall survival.2
During the study, patients will be randomized 1:1 into an experimental or control arm. During the control arm, patients will receive 177Lu-edotrerotide and an amino-acid solution. During the control arm, the best standard of care treatment will be used. Investigators can pick between 3 options:
“The most common form of NETs is gastroenteropancreatic and often develops metastatic disease, limiting treatment options. N.c.a. 177Lu-edotreotide has previously shown a favorable safety and efficacy profile in GEP-NETs and with COMPOSE we aim to also make it available to late-stage patients suffering from this hard-to-treat cancer indication,” said Steffen Schuster, CEO of ITM, in a press release. “We look forward to the opportunity of introducing our phase III COMPOSE trial to the global scientific community at the NANETS symposium, a key oncology event that features leading research, education, and emerging practices on NETs.”
In order to participate in the study, patients must be 18 years of age or older, have a confirmed diagnosis of unresectable, well-differentiated gastroenteropancreatic NETs, measurable disease, and be somatostatin receptor positive. Patients who have received prior peptide receptor radionuclide therapy, any major surgery within 4 weeks prior to randomization, other known malignancies, serious non-malignant disease, renal, hepatic, cardiovascular, or hematological organ dysfunction, or are breastfeeding are unable to participate.
In addition to being studied in gastroentreropancreatic NETs, 177Lu-edotreotide is also being studied in the phase 3 COMPETE trial (NCT03049189). This trial is looking at the agent in combination with everolimus for the treatment of inoperable, progressive, somatostatin receptor-positive, neuroendocrine tumors of gastroenteric or pancreatic origin.
Brain Cancer Awareness Month: Challenges and Innovations in Treatment
May 13th 2024In an interview with Targeted Oncology for Brain Cancer Awareness Month, Theodore Schwartz, MD, discussed the challenges of targeting brain tumors, emerging therapies, and strategies to overcome the blood-brain barrier.
Read More
Durvalumab Plus Chemo Continues to Improve Survival in Biliary Tract Cancer
April 16th 2024Results from a 3-year follow-up of the TOPAZ-1 trial showed that treatment with durvalumab plus chemotherapy in advanced biliary tract cancer continued to improve overall survival vs chemotherapy alone.
Read More
KEYNOTE-859 Outcomes Influence NCCN Guidelines on Pembrolizumab in Upper GI Cancer
April 10th 2024During a Case-Based Roundtable® event, David Zhen, MD, discussed how treatment of upper gastrointestinal cancer with pembrolizumab and chemotherapy is impacted by PD-L1 composite positive score, in the second article of a 2-part series.
Read More